Melanoma Vaccines

Seminars in Oncology

Volumn 34, Issue 6, 2007, Pages 516-523

  Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANVAXIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DENDRITIC CELL VACCINE; DNA VACCINE; GANGLIOSIDE; GANGLIOSIDE GM2; MELANOMA VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER SURVIVAL; CELL LYSATE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG MEGADOSE; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTOPENIA; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 36849052846     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.09.013     Document Type: Article

References (67)

1. Southam C.M. Applications of immunology to clinical cancer: Past attempts and future possibilities. Cancer Res 21 (1961) 1302-1316
2. Atkins M.B., Kunkel L., Sznol M., et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 6 suppl 1 (2000) S11-S14
3. Nasi M., Meyers M., Livingston P., et al. Anti-melanoma effects of R24, a monoclonal antibody against GD3. Vaccine Res 7 suppl 2 (1997) S155-S162
4. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100 (2003) 8372-8377
5. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
6. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23 (2005) 2346-2357
7. Dudley M.E., Wunderlich J.R., Yang J.C., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25 (2002) 243-251
8. Cormier J.N., Hijazi Y.M., Abati A., et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75 (1998) 517-524
9. Maeurer M.J., Gollin S.M., Martin D., et al. Tumor escape from immune recognition. Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98 (1996) 1633-1641
10. Trefzer U., Herberth G., Wohlan K., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110 (2004) 730-740
11. Somasundaram R., Swoboda R., Caputo L., et al. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 66 (2006) 3287-3293
12. Al-Batran S.E., Rafiyan M.R., Atmaca A., et al. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 65 (2005) 3937-3941
13. Belli F., Testori A., Rivoltini L., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 (2002) 4169-4180
14. Hicklin D.J., Marincola F.M., and Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5 (1999) 178-186
15. Kageshita T., Wang Z., Calorini L., et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 53 (1993) 3349-3354
16. Weishaupt C., Munoz K.N., Buzney E., et al. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res 13 (2007) 2549-2556
17. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8 (2002) 793-800
18. Murakami T., Cardones A.R., Finkelstein S.E., et al. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 198 (2003) 1337-1347
19. Shukuwa T., Katayama I., and Koji T. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod Pathol 15 (2002) 387-396
20. Langowski J.L., Zhang X., Wu L., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
21. Ahmadzadeh M., and Rosenberg S.A. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174 (2005) 5215-5223
22. Janji B., Melchior C., Gouon V., et al. Autocrine TGF-beta-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype. Int J Cancer 83 (1999) 255-262
23. Krasagakis K., Tholke D., Farthmann B., et al. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77 (1998) 1492-1494
24. Chen Q., Daniel V., Maher D.W., et al. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56 (1994) 755-760
25. Gerlini G., Tun-Kyi A., Dudli C., et al. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 165 (2004) 1853-1863
26. Nemunaitis J., Fong T., Shabe P., et al. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19 (2001) 239-247
27. + regulatory T cells. Immunol Rev 212 (2006) 60-73
28. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163 (1999) 5211-5218
29. + regulatory T cells in cancer patients. Blood 107 (2006) 2409-2414
30. Gregor P.D., Wolchok J.D., Ferrone C.R., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22 (2004) 1700-1708
31. Met O., Wang M., Pedersen A.E., et al. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 231 (2006) 247-256
32. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005) 741-750
33. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100 (2003) 4712-4717
34. O'Mahony D., Morris J.C., Quinn C., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13 (2007) 958-964
35. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 (2002) 2058-2066
36. Sosman J.A., Unger J.M., Liu P.Y., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node- negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20 (2002) 2067-2075
37. Morton D.L. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 25 (2007) 474s (abstr 8508)
38. Wallack M.K., Sivanandham M., Balch C.M., et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187 (1998) 69-77
39. Hersey P., Coates A.S., McCarthy W.H., et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 20 (2002) 4181-4190
40. Schadendorf D., Ugurel S., Schuler-Thurner B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (2006) 563-570
41. Livingston P.O., Wong G.Y.C., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12 (1994) 1036-1044
42. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
43. Ortqvist A., Hedlund J., Burman L.A., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351 (1998) 399-403
44. Rubins J.B., Puri A.K., Loch J., et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 178 (1998) 431-440
45. Parmiani G., Castelli C., Santinami M., et al. Melanoma immunology: Past, present and future. Curr Opin Oncol 19 (2007) 121-127
46. Cohen A.D., and Wolchok J.D. DNA vaccines for melanoma. In: Giaccone G., Schilsky R., and Sondel P.M. (Eds). Cancer Chemotherapy and Biological Response Modifiers vol 22 (2005), Elsevier, New Tork, NY 761-768
47. Cassaday R.D., Sondel P.M., King D.M., et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 13 (2007) 540-549
48. Wolchok J.D., Gallardo H., Perales M., et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. J Clin Oncol 25 (2007) 119s (abstr 3005)
49. Liao J.C., Gregor P., Wolchok J.D., et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6 (2006) 8
50. Bergman P.J., Camps-Palau M.A., McKnight J.A., et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24 (2006) 4582-4585
51. Schreiber K., Rowley D.A., Riethmuller G., et al. Cancer immunotherapy and preclinical studies: Why we are not wasting our time with animal experiments. Hematol Oncol Clin North Am 20 (2006) 567-584
52. Lee K.H., Wang E., Nielsen M.B., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163 (1999) 6292-6300
53. + T cells. J Immunol 165 (2000) 2287-2296
54. + T cells in patients with melanoma. J Immunol 175 (2005) 6169-6176
55. Perales M.A., Diab A., Cohen A.D., et al. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. J Immunol 177 (2006) 4159-4167
56. Anasetti C., and Mule J.J. To ablate or not to ablate? HSCs in the T cell driver's seat. J Clin Invest 117 (2007) 306-310
57. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 (1999) 1669-1678
58. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
59. Banchereau J., Palucka A.K., Dhodapkar M., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
60. Chang A.E., Redman B.G., Whitfield J.R., et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8 (2002) 1021-1032
61. Schuler-Thurner B., Schultz E.S., Berger T.G., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195 (2002) 1279-1288
62. Slingluff Jr. C.L., Petroni G.R., Yamshchikov G.V., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21 (2003) 4016-4026
63. Peterson A.C., Harlin H., and Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21 (2003) 2342-2348
64. + immunity. Clin Cancer Res 11 (2005) 7692-7699
65. O'Rourke M.G., Johnson M., Lanagan C., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52 (2003) 387-395
66. Di Pucchio T., Pilla L., Capone I., et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66 (2006) 4943-4951
67. Tuettenberg A., Becker C., Huter E., et al. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer 118 (2006) 2617-2627